Trials / Conditions / Refractory Medulloblastoma

Refractory Medulloblastoma

17 registered clinical trials studyying Refractory Medulloblastoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults NCT07087002	Stanford University	Phase 1
Recruiting	Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors NCT05278208	Nationwide Children's Hospital	Phase 1 / Phase 2
Active Not Recruiting	Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter NCT04284774	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors NCT03598244	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994	National Cancer Institute (NCI)	Phase 2
Completed	Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly NCT03526250	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652	National Cancer Institute (NCI)	Phase 2
Completed	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665	National Cancer Institute (NCI)	Phase 2
Completed	Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diff NCT02359565	National Cancer Institute (NCI)	Phase 1
Completed	Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02095132	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurren NCT01217437	National Cancer Institute (NCI)	Phase 2